Subject: Basic medicine
Subject: Clinical medicine
Subject: Health sciences
Subject: Other medical sciences
Year: 2021
Type: Article
Type: PeerReviewed
Title: The role of dehydroepiandrosterone sulphate and testosterone in erectile dysfunction in patients treated with 5 alpha reductase inhibitors
Author: Sofronievska, Maja
Abstract: Abstract: The pharmacological treatment of benign prostatic hyperplasia involves the use of mainly two groups of drugs: selective alpha 1 blocker and 5 alpha reductase inhibitors (5ARI). In patients who undergo 5ARI pharmacotreatment, adverse effects such as sexual disturbances such as erectile dysfunction and decreased libido may occur. The purpose of this study is to investigate the occurrence of these side effects, particularly erectile dysfunction in order to predict and overcome them more easily. We conducted a controlled prospective pharmaco-epidemiological study to evaluate the side effects with the use of 5ARI in 250 men with benign prostatic hyperplasia (BPH). Erectile function was assessed at the time of the initiation of therapy and at the time of active use of therapy in two consecutive periods of 6 months and 12 months. We evaluated two groups of patients: the control group of patients treated with alpha 1 blocker (tamsulosin), and the investigated group of patients treated with combination therapy of alpha 1 blocker (tamsulosin) and 5 alpha reductase inhibitors (dutasteride). The evaluation was conducted through questionnaires: IPSS (International Prostate Score System) to calculate the symptoms of benign prostatic hyperplasia (light, medium or severe) and IIEF-5 (International Index for Erectile Function-5) questionnaire for calculating erectile function. During the study measurement of serum levels of testosterone and dehydroepiandrosterone sulphate were performed respectively. Statistical results of nonparametric group analysis showed that erectile dysfunction appeared in 27 patients (22.5%) in the investigated group after 6- and 12-months therapy respectively which was statistically significant (p<0,05). Twenty six of these patients (96,3%) have had lowered testosterone and dehydroepiandrosterone sulphate serum levels (p<0,05). As a conclusion we recommend investigation of testosterone and DHEAS serum levels prior to starting therapy should be considered valuable in order to avoid 5ARI related erectile dysfunction. Keywords: BPH, erectile function, testosterone, dehydroepiandrosterone-sulphat
Publisher: Knowledge International Journal (KIJ)
Relation: https://eprints.ugd.edu.mk/29976/
Identifier: oai:eprints.ugd.edu.mk:29976
Identifier: https://eprints.ugd.edu.mk/29976/1/The%20role%20of%20dehydroepiandrosterone%20sulphate%20and%20testosterone%20in%20ED.pdfIdentifier: Sofronievska, Maja (2021) The role of dehydroepiandrosterone sulphate and testosterone in erectile dysfunction in patients treated with 5 alpha reductase inhibitors. Knowledge International Journal (KIJ), 46 (4). pp. 505-510. ISSN 1857-923X / 2545 - 4439 printed
Identifier: UDK 37
